Both trials met their primary endpoints, indicating a significant improvement in patients treated with the drug.

GSK's depemokimab met key endpoints in phase 3 trials for chronic rhinosinusitis with nasal polyps (CRSwNP), showing promise ...

GSK plc GSK announced positive data from the phase III ANCHOR-1 and ANCHOR-2 studies, which evaluated its pipeline candidate, ...

UK pharma major GSK today announced positive headline results from two Phase III clinical trials, ANCHOR-1 and ANCHOR-2, ...

Depemokimab has already shown its potential as a therapy for severe asthma in two other phase 3 trials – SWIFT-1 and SWIFT-2 ...

GSK’s blockbuster hopes for depemokimab remain on track after the investigational long-acting asthma treatment has also been ...

GSK announces positive phase III results from ANCHOR trials for depemokimab in chronic rhinosinusitis with nasal polyps: London, UK Tuesday, October 15, 2024, 10:00 Hrs [IST] GSK ...

The company has set high expectations for depemokimab, which it is also advancing in three other inflammatory diseases, including asthma.

The approval in adolescent patients with CRSwNP was also supported by pharmacokinetic data from adult and pediatric patients aged 12 years and older with moderate to severe asthma and adult ...

Following Priority Review, Dupixent is now available to patients as young as 12 years with inadequately controlled CRSwNP Current treatment options leave many patients with uncontrolled disease ...

GSK plc (LSE/NYSE: GSK) 宣布其用于治疗慢性鼻窦炎伴鼻息肉(CRSwNP)的药物depemokimab在ANCHOR三期临床试验中取得积极成果。根据新闻稿，该试验达到了主要终点，与安慰剂加标准治疗相比，在52周内显著减少了鼻息肉大小和鼻塞程度。 Depemokimab是一种超长效生物制剂，每半年给药一次，在靶向和抑制与鼻息肉生长和阻塞相关的炎症方面显示出了前景。 GSK高级副 ...

CRSwNP is a chronic disease of the upper airway, driven in part by type 2 inflammation, that obstructs the sinuses and nasal passages. It can lead to breathing difficulties, nasal congestion and ...